Why the study?
CMV-DNAemia may misinterpret active viral replication in patients receiving letermovir due to abortive infection, and alternative methods are laborious and non-standardized.
Does a new CMV-RNAemia test accurately identify active viral replication to guide pre-emptive or prophylaxis strategies in transplant recipients receiving letermovir?
Does a new CMV-RNAemia test accurately identify active viral replication to guide pre-emptive or prophylaxis strategies in transplant recipients receiving letermovir?
A new CMV-RNAemia test is being evaluated as a potentially more accurate marker of active viral replication in transplant recipients receiving letermovir, overcoming the limitations of CMV-DNAemia.
Answers are grounded in this paper and cite their sources.
Questions CMV-DNAemia accuracy under letermovir; leaves open validation of alternative replication markers.
Currently, the quantification of cytomegalovirus (CMV) DNA in blood samples (CMV-DNAemia) represents the gold standard for identifying active viral replication, preventing CMV-related disease, and monitoring response to drugs targeting CMV-DNA polymerase (1–5). The recent introduction of letermovir (LMV) showed that CMV-DNAemia may not be an accurate marker of active viral replication (6–9). Indeed, by blocking the terminase complex, LMV induces the release of free CMV-DNA fragments (abortive infection), which could lead to potential misinterpretation of molecular testing results (1, 6–9). Additional methods, such as CMV-viremia (shell vial method) and CMV-DNAemia post-DNase (DNase test), could be used to prove active viral replication. CMV viremia detects CMV infectious particles in cell culture, whereas the DNase test exploits the digestion activity of DNase I added to the sample before extraction to differentiate free naked DNA from the genome encapsidated into virions. Both methods, therefore, identify the presence of infectious virions in blood samples. However, the procedures are laborious and not standardized (8). This pilot study evaluates the clinical utility of a new CMV-RNAemia test to identify active viral replication and guide pre-emptive or prophylaxis strategies in transplant settings, especially in patients receiving LMV.
No takes yet. Share an insight, caveat, or question.
Piccirilli et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: